<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416388</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-2010-03</org_study_id>
    <nct_id>NCT02416388</nct_id>
  </id_info>
  <brief_title>Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR</brief_title>
  <acronym>BIG-1</acronym>
  <official_title>Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, multicenter phase II/III study with multiple randomization phases at
      differents stages of AML treatment (induction, consolidation and HSCT where applicable) is
      designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient
      strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following
      allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC)
      conditioning, will also be evaluated. With an adaptative design, this clinical trial could
      test up to 3 novel AML agents of interest.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>For randomizations R1 (idarubicine vs daunorubicine) and R2 (HDAC vs IDAC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IV</measure>
    <time_frame>100 days</time_frame>
    <description>For randomization R3 : GvHD prophylaxis study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>18 months</time_frame>
    <description>For randomizations R4</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">3100</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>R1-IDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idarubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1-DAUNO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daunorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2-HDAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2-IDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3-MAC-MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate and mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3-MAC-MPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine and mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3-RIC-CICLO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3-RIC-MPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine and mycophenolic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R4-VOS-IDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose cytarabine and vosaroxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R4-IDAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermediate dose cytarabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Induction chemotherapy :
Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)
+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate &lt; 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).</description>
    <arm_group_label>R1-IDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Induction chemotherapy :
Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)
+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate &lt; 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).</description>
    <arm_group_label>R1-DAUNO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HD Cytarabine</intervention_name>
    <description>Consolidation chemotherapy course (s) :
-High dose cytarabine: 3g/m² /12h on D1, D3 and D5
For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)
Up to 3 consolidation courses, depending on the patient AML risk group</description>
    <arm_group_label>R2-HDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>GvHD prophylaxis post allogeneic SCT :
-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100</description>
    <arm_group_label>R3-MAC-MPA</arm_group_label>
    <arm_group_label>R3-RIC-CICLO</arm_group_label>
    <arm_group_label>R3-RIC-MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>GvHD prophylaxis post allogeneic SCT :
-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11</description>
    <arm_group_label>R3-MAC-MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid (MPA)</intervention_name>
    <description>GvHD prophylaxis post allogeneic SCT :
720 mg BID from D0 to D+28 for HLA-identical siblings
720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors</description>
    <arm_group_label>R3-MAC-MTX</arm_group_label>
    <arm_group_label>R3-MAC-MPA</arm_group_label>
    <arm_group_label>R3-RIC-MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vosaroxin</intervention_name>
    <description>Consolidation chemotherapy course (s) :
-70 mg/m² on D1 and D4</description>
    <arm_group_label>R4-VOS-IDAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ID cytarabine</intervention_name>
    <description>Consolidation chemotherapy course (s) :
-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5
For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)
Up to 3 consolidation courses, depending on the patient AML risk group</description>
    <arm_group_label>R2-IDAC</arm_group_label>
    <arm_group_label>R4-VOS-IDAC</arm_group_label>
    <arm_group_label>R4-IDAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (at diagnosis) :

          1. Age ≥ 18 years and &lt; 61 years

          2. With a newly diagnosed de novo or secondary type AML (post myelodysplastic syndrome
             MDS or therapy-related AML)

          3. No prior treatment for AML, with the exception of hydroxyurea

          4. ECOG performance status ≤ 3

          5. No contraindication to anthracyclines : decompensated or uncontrolled heart failure,
             recent myocardial infarction, current signs of cardiac impairment, uncontrolled
             arrhythmias, LVEF (left ventricular ejection fraction) &lt; 50%

          6. Total bilirubin ≤ 2 x upper limit of normal (UNL), ASAT(SGOT) and ALAT (SGPT) ≤ 2.5 X
             UNL, creatinine &lt; 150 µmol/l, unless AML-related out of range values

          7. Women of childbearing potential should use appropriate methods of contraception

          8. Health insurance coverage

          9. Signed informed consent

        Exclusion criteria (at diagnosis) :

          1. Patients with acute promyelocytic leukemia (APL), as confirmed either by t(15;17) or
             by the presence of PML-RARA fusion transcripts

          2. Patients with core binding factor (CBF) AML, as confirmed either by t(8;21), t(16,16)
             or inv(16), or by fusion transcripts resulting from these cytogenetic abnormalities
             (RUNX1-RUNX1T1, CBFB-MYH11).

          3. Patients with secondary AML arising from myeloproliferative disorders previously known
             according to the 2008 WHO classification

          4. Patients with Ph1+ AML or previous Ph1+ disorder (chronic myelogenous leukemia)

          5. Severe pshyciatric or organic disorder, supposed to be independent from AML, that
             would contraindicate treatment, including allogeneic HSCT

          6. No psychological, familial, social, or geographic reason that would compromise
             clinical follow up

          7. History of uncontrolled cancer for the last 2 years, with the exception of basal cell
             carcinoma or carcinoma in situ of the cervix

          8. Uncontrolled severe infection

          9. Patients with positive serology for HIV-1 and -2, or HTLV -1 and -2, or active
             hepatitis virus B or C infection

         10. Pregnant or lactating women

         11. Legal incapacity (patients under tutorship, curatorship or judicial protection)

        For randomization R4-VOS (post-induction/salvage):

        Inclusion criteria

          1. Patients enrolled in the BIG-1 trial at diagnosis

          2. Patients achieving first CR/CRp/CRi after induction or salvage therapy (within 15 days
             before R4-VOS)

          3. Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic
             classification

          4. Patients randomized to R2-IDAC arm (intermediate dose cytarabine)

          5. ECOG performance status ≤ 2

          6. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition
             (MUGA) scan or echocardiogram (ECHO)

          7. Local clinical laboratory values as follows:

               -  Serum creatinine ≤ 2.0 mg/dL

               -  Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) ≤ 2.5 X ULN

               -  Alanine aminotransferase (ALT) ≤ 2.5 X ULN

          8. Signed written informed consent for vosaroxin study (R4-VOS)

          9. Women of childbearing potential must have a negative pregnancy test within 8 days
             before randomization R4-VOS and commit to the use of effective contraception during
             the period of treatment and up to 36 days after vosaroxin has been stopped. Men must
             use effective contraception during the treatment period and up to 96 days after
             vosaroxin has been stopped.

        Exclusion criteria

          1. Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome,
             uncontrolled fever

          2. Documented uncontrolled fungal infection (positive blood test and cultures)

          3. History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or
             transient ischemic attack (TIA) in the 3 months before randomization

          4. Patient under hemodialysis (HD) or peritoneal dialysis (PD)

        For randomization R3 (before AlloHSCT):

        Inclusion criteria

          1. Patients enrolled in the BIG-1 trial at diagnosis

          2. Patients achieving first CR after induction or salvage therapy

          3. Patients belonging to the intermediate AML risk group as defined in the protocol BIG-1

          4. Signed informed consent for R3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathilde Hunault, PD</last_name>
    <email>MaHunault@chu-angers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annabelle Boussault</last_name>
    <phone>+ 33 241 356 490</phone>
    <email>annabelle.boussaul@chu-angers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Amiens Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Marolleau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Hunault</last_name>
      <email>MaHunault@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Al Jijakli</last_name>
      <email>ahmadkanj.aljijakli@ch-argenteuil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Banos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Larosa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Beziers</name>
      <address>
        <city>Beziers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Saad</last_name>
      <email>alain.saad@ch-beziers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Gardin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Pigneux</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Dr Duchenne</name>
      <address>
        <city>Boulogne sur Mer</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bachra Choufi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle Guillerm</last_name>
      <email>gaelle.guillerm@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Chantepie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du parc</name>
      <address>
        <city>Castelnau Le lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Exbrayat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Cergy Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioana Vaida</last_name>
      <email>ioana.vaida@ch-pontoise.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Valère Malfuson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie Ravinet</last_name>
      <email>aravinet@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Salanoubat</last_name>
      <email>celia.salanoubat@ch-sud-francilien.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Caillot</last_name>
      <email>denis.caillot@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Bemba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Cahn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rousselot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure STALNIKIEWICZ</last_name>
      <email>lstalnikiewicz@ch-lens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Quesnel</last_name>
      <email>bruno.quesnel@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Cambier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Turlure</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard (CLB)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amine Belhabri</last_name>
      <email>amine.belhabri@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Thomas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Vey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamilé Frayfer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Metz Thionville_Hôpital de Mercy</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Dorvaux</last_name>
      <email>v.dorvaux@chr-metz-thionville.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yosr Hicheri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Ojeda-Uribe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peterlin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauris Gastaud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Cluzeau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jourdan</last_name>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Bouscary</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madalina Uzunov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Suarez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ollivier Legrand</last_name>
      <email>ollivier.legrand@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Raffoux</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Sahnes</last_name>
      <email>laurence.sahnes@ch-perpignan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar Gallego-Hernanz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Himberlin</last_name>
      <email>chimberlin@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bernard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Victor Provo</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Plantier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Lemasle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>St Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Vargaftig</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>St Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle Tavernier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lioure</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Recher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan</last_name>
      <email>emmanuel.gyan@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Fernandes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois_CHU Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Roth-Guepin</last_name>
      <email>g.roth-guepin@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane De Botton</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

